

Reproductive Toxicology

Elsevier Editorial System(tm) for
Manuscript Draft

Manuscript Number: 5246R1

Title: Arterial dysgenesis and limb defects: clinical and experimental examples

Article Type: SI: Dev-Angio

Keywords: vascular transition; thalidomide; vascular disruption; human embryo; vertebrate embryo; clubfoot and vertical talus; PFFD; holt-oram syndrome

Corresponding Author: Dr. Neil Vargesson,

Corresponding Author's Institution: University of Aberdeen

First Author: Neil Vargesson

Order of Authors: Neil Vargesson; David R Hootnick

Manuscript Region of Origin: UNITED KINGDOM

Abstract: Limb malformations are amongst the most common and visible birth effects. Causes have been purported to include genetic aberrations as well as teratogens, such as thalidomide. Here we review the evidence for vascular disruption in the genesis of limb malformations through abnormal arterial transition and from events such as amniocentesis, uterine constriction, and through teratogen exposure. We use several clinical and experimental examples and highlight the need to understand more about the role the vascular system plays in the molecular mechanisms underpinning normal limb development.

Abstract

Limb malformations are amongst the most common and visible birth effects. Causes have been purported to include genetic aberrations as well as teratogens, such as thalidomide. Here we review the evidence for vascular disruption in the genesis of limb malformations through abnormal arterial transition and from events such as amniocentesis, uterine constriction, and through teratogen exposure. We use several clinical and experimental examples and highlight the need to understand more about the role the vascular system plays in the molecular mechanisms underpinning normal limb development.

1 **Arterial dysgenesis and limb defects: clinical and experimental examples**
2
3
4

5
6 Neil Vargesson^{1,*} and David R. Hootnick²
7
8
9

- 10
11 1. School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences.
12 University of Aberdeen. Foresterhill. Aberdeen. AB25 2ZD. UK.
13 2. Departments of Orthopedic Surgery, Cellular and Developmental Biology, and
14 Pediatrics, SUNY Upstate Medical University, 1133 Weiskotten Hall, 750 E Adams
15 St. Syracuse. NY 13203. USA.
16
17
18
19

20 * Author for correspondence: n.vargesson@abdn.ac.uk; nvargesson@gmail.com
21
22
23
24
25
26

27 Key Words:

28 vascular transition, limb malformation, thalidomide, mifepristol, vascular disruption, human
29 embryo, vertebrate embryo, clubfoot, vertical talus, PFFD (proximal femoral focal deficiency),
30 Holt-Oram Syndrome
31
32
33

34 **Abstract**

35 Limb malformations are amongst the most common and visible birth effects. Causes have been
36 purported to include genetic aberrations as well as teratogens, such as thalidomide. Here we
37 review the evidence for vascular disruption in the genesis of limb malformations through
38 abnormal arterial transition and from events such as amniocentesis, uterine constriction, and
39 through teratogen exposure. We use several clinical and experimental examples and highlight the
40 need to understand more about the role the vascular system plays in the molecular mechanisms
41 underpinning normal limb development.

42
43 **Blood vessel formation and development**

44 Blood vessels are essential for embryogenesis as well as for normal physiological function
45 throughout life. In the embryo the first primitive vessels are formed by vasculogenesis, where
46 endothelial cell precursors congregate and form vascular tubes for blood cells to pass through.
47 This initial network is expanded upon through angiogenesis, where new vessels form through the
48 proliferation and migration of endothelial cells and vascularize previously avascular tissues
49 (Figure 1) [1]. Many molecules are involved in angiogenesis and one of the main triggers of
50 angiogenesis is hypoxia which stimulates the expression of Vascular Endothelial Growth Factor
51 to cause the proliferation and migration of endothelial cells into previously avascular tissue [1-3].
52 In the rapidly developing early embryo, angiogenesis occurs in the majority of tissues to ensure
53 good oxygen and nutrient supply and the removal of waste products. Vessels can recruit a
54 smooth muscle coating which stabilizes the vessel and also maintains blood pressure, and until
55 the loss of the smooth muscle coat, the vessel then undergoes quiescence (Figure 1).

56
57 **Limb development and vascularisation of the developing limb**

58 In the developing human embryo, the upper limbs form around day 26 (approx. week 3.7) after
59 fertilization followed 24hrs later by the lower limbs [4]. The limbs grow out from the body under
60 the control of specialized signaling regions, specifically the Zone of Polarising Activity (ZPA)
61 and the Apical Ectodermal Ridge (AER). These two regions in particular signal to the
62 mesenchyme to induce mesenchymal cell proliferation and limb outgrowth as well as control
63 differentiation of the bones and tissues of the limbs (Figure 2A) [1, 5]. As the limbs grow out
64 from the body, the multitude of tissues including muscle, tendon, nerve and bones of the limb
65 differentiates in a proximal to distal manner, that is the humerus/femur is specified and laid down
66 before the radius/fibula and ulna/tibia and finally the digits (Figure 2A). The vessel patterns
67 change accordingly (Figure 2B). Vessel regression in the areas where the long bones and the
68 future digits form occurs and this process also marks a change in the vessel pattern to the adult
69 state (Figure 2B). By around day 56 (approx. week 8) human limbs are fully complete with
70 fingers/toes etc.

71
72 The molecular and morphological events that underlie limb development and some limb
73 malformations are becoming clearer and have largely been ascertained from animal models
74 particularly the chicken and mouse (Figure 2A) [5-8]. Yet, the role of the rapidly changing
75 vasculature in the molecular and mechanistic events underlying limb development are largely
76 unknown.

77
78 Most of our understanding of limb vascularization has come from animal model systems and
79 studies in human embryos/fetuses from the beginning of the 20th century [9, 10]. There are some

80 differences in the arterial vascularization of the upper and lower limbs. Following the initiation
81 of limb development, the main artery supplying the upper limb buds is the subclavian artery and
82 from this a capillary network rapidly forms (via angiogenesis) throughout the outgrowing limb
83 bud (Figure 2B) [1, 3, 11]. As limb development proceeds the subclavian artery name changes
84 to become the brachial artery in the upper limb. The brachial artery itself later gives rise to the
85 ulnar and radial arteries in the forearms. In the lower limbs, arterial vascularization also proceeds
86 through angiogenesis but is a little more complicated. Initially primitive arteries from the
87 umbilical artery traverse the forming limb bud as the axial and external iliac arteries. The
88 external iliac artery eventually becomes the femoral artery, supplying the upper leg. The axial
89 artery traverses the outgrowing leg bud to supply the distal regions of the leg bud and further
90 divides into the fibular (peroneal) arteries (Figure 3). As the leg bud develops, there is further
91 splitting of the femoral artery to produce further arterial supply to the forming bones of the limbs
92 (Figure 3).

93 In addition, there is also vessel regression as well as formation of composite arteries. The fibular
94 (peroneal artery), which primarily provides the blood supply to the fibula, is one such composite
95 artery; it contains four elements/segments of three earlier embryonic arteries, which have
96 undergone repeated rounds of angiogenesis and stabilization to achieve the adult configuration
97 (Figure 3) [9, 10, 12].

98

99 **Embryonic to adult arterial transition**

100 Elegant analyses in human embryos have demonstrated that, in early limb buds, a capillary
101 network is evident. As development proceeds, the vascular pattern differentiates into defined
102 vessels initially in the proximal tissue and then finally in the distal tissue, where the digits form
103 last (Figure 3) [9, 10, 13-16]. Approximately five weeks after fertilization, single axial arteries of
104 both the upper and lower extremities begin the transition to more complex arterial patterns
105 (Figure 3). The arterial transitions coincide with the long bone transitions from mesenchymal
106 primordia (anlage) to chondral and then osseous structures. Arterial alterations occur prior to and
107 during the organization of the muscles, tendons and nerves but after specification/patterning of
108 the limb is completed [17]. The upper and lower human limb embryonic arterial transitions have
109 been completed prior to the 8th week of development, resulting in the adult arterial pattern
110 (Figure 3) [9, 10 13, 14, 18].

111

112 In the chicken embryo the transition of the arterial pattern of the limbs from embryonic to mature
113 state has occurred by approximately day 8 of development. As in the the human embryo, the
114 arterial transitions occur during and after the specification and patterning of the bony elements
115 has occurred. The arterial transition likely allows the bones of the limb to form correctly and in
116 the correct positions [11, 19]. Much of our understanding of the processes of limb
117 vascularization has come from studying chicken limb development [1, 2, 11, 19]. Unlike vessels
118 in other regions of the chicken embryo, the early developing limb vascular network remains
119 devoid of vascular smooth muscle cells, which lend protection and support to the vessels. Not
120 until relatively late in limb development, after the adult vascular pattern has started to become
121 established are vascular smooth muscle cells seen upon limb vessels (Figure 2B) [11, 20].
122 Indeed, the brachial artery starts to recruit smooth muscle first, in chicken embryos from around
123 HH St25 (E5; about 2.5 days after limb development has started, which is relatively late in
124 development as the limbs buds are well advanced in outgrowth) (Figure 2A). Other vessels only
125 start recruiting smooth muscle much later in development [11, 20]. By comparison, vessels in

126 other regions of the embryo, including the head, contain vascular smooth muscle coats by these
127 stages [1, 20, 21]. Smooth muscle protects the vessel and prevents angiogenesis. In order for
128 angiogenesis to re-occur, the smooth muscle coat needs to be lost [1]. Since the developing limbs
129 are rapidly growing and changing, the developing limb requires a vasculature that adapts to the
130 changing environment quickly; thus, a smooth muscle coat would be an obstacle to early
131 development. Absence of the smooth muscle coat presumably permits rapid changes in limb
132 outgrowth to occur. However, this also makes the vessels more susceptible to potential injury
133 and damage [1, 20].

134

135 **Embryonic to adult arterial transition failure and limb defects**

136 Whilst there may be a variation of limb arterial branching patterns in up to 20% of normal adult
137 humans [13], a failure of correct vessel patterning or a failure of the embryo to adult vascular
138 transition has been associated with limb defects in humans [12, 22-27] and in animal models [20,
139 28-31].

140

141 Indeed, through radiographic and pathologic analyses of dysmorphic human lower limbs, the
142 combined associations of reduction or absence of the proximal femur [22, 32], the fibula [33]
143 and midline metatarsals [23] suggests the possibility of a temporal and anatomic linkage of the
144 skeletal changes to failure of embryonic arterial transition, when the long bones are first forming
145 [9, 10, 12, 15, 18]. Arteriography of a series of such affected limbs further revealed abnormal
146 arterial patterns, which have demonstrated persistence of primitive embryologic arteries, absence
147 of one of the normal adult arteries and failure of formation of the plantar arch of the foot [12, 32-
148 35].

149

150 For example, some cases of congenital fibular deficiency (Figure 4A-C) [12] and radial aplasia
151 [36] have been described indicating the vascular pattern of the limbs appears to be intermediate
152 between an embryonic and adult state, suggesting the long bones might not form or might form
153 incorrectly due to the misplacement or mis-positioning of the vessels. Furthermore, the foot is
154 typically supplied with three arteries, the posterior tibial, anterior tibial and the fibular (peroneal)
155 (Figure 3B). In the debilitating condition clubfoot, where the foot points downward, toes are
156 turned inward and the bottom of the foot, that would normally be walked on is twisted inward,
157 the anterior tibial artery is most consistently reduced in length in the most severely deformed
158 limbs and absent in the distal foot. The lack of alternative arterial pathways has been proposed to
159 explain why the foot ‘clubs’ in such cases (Figure 4D) [17, 24, 35, 37, 38]. In contrast, in cases
160 of the congenital vertical talus deformity, where the foot is pointed upwards, rigidly, causing the
161 toes to point up and out with loss of the arch of the foot, the posterior tibial artery is most
162 consistently significantly reduced or sometimes missing [24, 34, 35, 38]. Similarly, arteriography
163 of the limbs of children with proximal femoral focal deficiency (PFFD; congenitally short limb),
164 where the femur may be significantly reduced in length and can vary morphologically from just a
165 distal remnant of the femur to an almost normal sized femur, has revealed distinctly consistent
166 arterial changes in a majority of the affected limbs [32]. The changes may include reduction of
167 the diameter and length of the femoral arteries and/or preservation of the primitive sciatic
168 (ischadic) artery [32].

169

170 An abnormal arterial pattern in the developing limb could put the limb at risk for subsequent
171 malformation as, for example, there may be a reduced potential for collateral vascular circulation

172 resulting in tissue damage or loss. Conditions that antagonise blood flow through the remaining
173 arteries could then lead to tissue damage. This tissue damage could, in turn, interfere with the
174 developmental specification or differentiation of limb structures, leading to bony and/or soft
175 tissue abnormalities [12, 17, 24, 26, 33, 37].

176

177 **Timing of arterial dysgenesis**

178 Limb development and arterial transition occur between 5 and 8 weeks of human embryonic
179 development. This coincides with several periods of very rapid growth, considering that the
180 crown rump length of 10 mm at 5½ weeks grows to 20 mm at 7 weeks, thus effectively doubling
181 in length over a ten day period. The next most significant period of growth occurs between 7 and
182 8 weeks, over a seven day period, when the embryo enlarges from a crown rump length of 20
183 mm to a crown rump length of 30 mm. That is a 50% enlargement over a seven day period [4,
184 39]. During these times, the outgrowth of the upper and lower extremities is rapidly progressing,
185 after the specification of the limbs has begun and while the embryonic arterial alterations are
186 occurring [4, 12, 17, 37, 39]. Since the critical period for the initiation of bone development,
187 beginning as mesenchymal condensations, occurs subsequent to the fifth week of embryonic life,
188 coinciding with the time that the adult arterial pattern of vessels is emerging, it is possible that
189 both the arterial and skeletal systems simultaneously are mutually vulnerable to teratogenic
190 insults. Thus, the maldevelopment of the bones and the embryonic arterial pattern may be
191 intimately related [23, 33]. The evidence of embryonic arterial dysgenesis in association with a
192 variety of skeletal malformations and deletions has provided an explanation for the timing,
193 pathogenesis and distribution of some limb malformations.

194

195 Indeed, comparisons of the estimates of the upper femoral vs. lower leg dysmorphologies
196 suggest that the estimated timings of the respective arterial embryonic dysgeneses are associated
197 with the skeletal dysmorphologies observed. These findings are consistent with a progressively
198 more distal model of arterial development, after the completion of limb specification [9, 10, 12,
199 17, 18, 23, 32, 37]. Indeed, the critical time for connection between the femoral artery and the
200 sciatic (ischiodic) artery in the femoral region of the lower extremity has been estimated to occur
201 between the 12 and 14 mm stages of embryonic development (approximately week 6) (Figure
202 3B) [9, 10, 32]; the critical time for arterial changes of the more distal part of the lower extremity
203 in the tibial and fibular region has been estimated to occur between the 19 and 22 mm stages of
204 embryonic development (approximately week 7) (Figure 3B) [12, 23]. Hence many limb
205 malformations may be interpreted as post-specification events, which occur after the bony
206 elements have been specified but which are then damaged, diminished or radiologically absent
207 through failure or loss of appropriate vascularization resulting in smaller or missing bones. More
208 elementally, such careful dissections and/or detailed imaging of human malformed limbs has
209 revealed that such limb malformations possess an arterial pattern typical of embryonic stages
210 and/or missing or misplaced vessels consistent with a failure of correct vascularization of the
211 involved bone [12, 17, 22, 23, 32, 33, 34, 35, 37]. Failure of arteries to develop to vascularize the
212 condensing cartilage precursor of the long bones will have intuitively resulted in the loss or
213 reduction in the length of the long bone (Figure 4). For example, late arterial invasion of the tibia
214 has been linked to the shortening and bending of the bone due to a delayed formation of the
215 perichondral ring, which encases the diaphysis (growth plate) of the long bones [33, 40].
216 Likewise, in limbs with PFFD, a significantly reduced arterial supply to the femur has been
217 identified that is linked to femoral shortening [32]. Further, the distal 2/3 of the fibula is supplied

218 by the fibular (peroneal) artery, whilst the proximal 1/3 is supplied by the anterior tibial artery;
219 thus, loss of either one of these vessels during fibula differentiation might result in fibula
220 deficiency or diminution [9, 10, 12]. Finally, in the upper limb, loss of the radial artery has been
221 purportedly linked to the underlying cause of radial aplasia (loss of the radius) [36].
222

223 The failure of arteries to vascularize their respective bony precursors could explain many limb
224 abnormalities including long bone loss, long bone bending as well as changes to digital patterns
225 due to the loss of or shortening of the long bones. Given the arterial transition occurs as the
226 bones have been specified and are starting to condense, the damage is thus, post-specification.
227

228 What could cause the blood vessels to not form correctly, or fail to transit to the adult state or
229 simply mispattern to cause limb anomalies?
230

231 **Molecular changes resulting in vascular disruption**

232 We know there are many human (and animal) limb defects associated with genetic mutations and
233 signaling changes [6, 7]; perhaps these are caused in early development before specification of
234 the bony elements or perhaps the resulting signaling changes alters vascularization of the
235 developing limbs and the arterial transition and branching events? For example, in some patients
236 with Holt-Oram Syndrome, a condition caused by a mutation in the gene *Tbx5*, upper limb
237 reduction ranging in severity from loss of the thumb to phocomelia is seen [41]. A reduced
238 peripheral vasculature in the affected limb/s has been reported in some patients [42]. Whether
239 this is secondary to the limb malformation or could actually be responsible is unclear.
240

241 Furthermore, recent work in animal models does suggest that failure of the forming bones to
242 receive the correct vascularization at the right time does result in bone outgrowth failure. For
243 example, a study where the neurotrophic factor, *TrkA*, essential to direct innervation and
244 promote vascularization of the outgrowing bone, when knocked out in mouse embryos result in
245 smaller bones in the limb due to a failure of vascularization of the bone [43]. Moreover,
246 molecular signals essential for blood vessel formation and identity, such as the Ephrins, members
247 of the Notch signaling pathway and members of the VEGF signaling pathway, are also essential
248 for proper bone vascularisation [44, 45]. Thus, if molecular signals fail to induce correct
249 vascularization of the forming bones, those bones do not form correctly.
250

251 **Trauma during pregnancy leading to arterial dysgenesis or vascular disruption**

252 *-Occlusion of vessels*

253 Pregnancy significantly increases the chances of thrombotic events, frequently due to changes in
254 blood coagulation whilst pregnancy is ongoing to prevent excess blood loss during pregnancy
255 and childbirth [46]. However, this could also increase the chance of thrombotic events in the
256 embryo. Some studies have proposed that vessel occlusion in the embryo through thrombi
257 through the placenta or from the heart or injured tissue could result in tissue damage leading to
258 malformation in humans [25, 27, 47, 48] and in animals [29, 31, 49].
259

260 Indeed, one study in chicken embryos demonstrated that following occlusion of the carotid
261 arteries severe brain anomalies such as anencephaly could be induced [49]. The study simply
262 demonstrates that the carotid arteries were missing and tissue distal to the occlusion never
263 formed [49]. This is an example of downstream tissue loss after vascular obstruction.

264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309

-Hemorrhage

Hemorrhage early in embryogenesis has also been linked in the genesis of malformations [50-52]. Indeed localized hematomas have been observed in spontaneously aborted human fetuses, without determination that the hematoma was the cause of the fetal death [53]. In addition focal hematomas or hemangiomas have been observed on the forehead of thalidomide damaged babies [51, 54, 55]. Hemorrhage induction in rat embryos through injection of drugs like aspirin [56] or through amniocentesis [57] has been shown to result in limb defects in rat fetuses, where increased uterine contractions in a smaller uterine space are purported to have caused damage, specifically via hemorrhaging, in the forming hand and footplates of the embryos; this can result in constriction bands, loss of digits and acrosyndactyly [57]. Similarly, in chicken embryos, after vessels were physically injured resulting in hemorrhage, embryonic development was impaired [52]. The hemorrhage most likely initiated a failure of differentiation of mesoderm and interfered with signaling processes, resulting in such dysmorphologies.

These events can result from external influences such as drug exposure (see next section) or through trauma, even from procedures that are seemingly simple. As, for example, amniocentesis, a method of analysis of the chromosome karyotype of the embryo/fetus involves aspirating amniotic fluid. It can lead to uterine constriction due to the reduction in amniotic fluid volume, resulting in damage to the limbs. Moreover, chorionic villus sampling, also used as a prenatal diagnostic tool, has been linked to terminal transverse limb malformations through disruptive vascular events, through hemorrhaging or cell death/tissue loss and/or hemangioma formation [58]. Although these events rarely occur, and most procedures occur without untoward consequences, these studies do highlight the need to monitor pregnancies without reduction of amniotic fluid to minimise damage to the extremities if uterine constriction does occur. In addition, placental damage itself from vascular insufficiency or from trauma to the uterus could result in thrombi that occlude vessels or cause hemorrhaging in the placenta restricting blood flow to the embryo potentially resulting in growth retardation of embryonic tissues [58].

Drugs taken during pregnancy leading to vascular disruption

-Thalidomide

Of course, environmental influences can also cause vascular anomalies in embryos, these include exposure to drugs like phenytoin, cocaine and valproate [58-60]. Perhaps the most infamous are thalidomide and more recently, misoprostol.

Thalidomide has been shown to be antiangiogenic in rabbit and rodent cornea assays [61, 62] and in chicken and zebrafish embryos [21, 63-66]. Indeed, the drugs antiangiogenic action is widely viewed as part of the key in the drugs teratogenic actions where the drug may target angiogenic, smooth muscle negative vessels resulting in their loss, or preventing them to transition to an adult state as well as then resulting in changes in molecular signaling pathways and ultimately tissue loss/malformation [67- 69].

It is of further interest to note that several studies in thalidomide survivors (children and adult) with limb anomalies, have reported cardiovascular malformations and vascular changes and/or missing vessels in the limbs which might help explain the damage [70, 71].

310
311 The hypothesis is that thalidomide induces vessel loss or may interfere with the vascular
312 transition which could lead to localized cell death resulting in missing or lost tissue, resulting in
313 bony elements being shorter or lost [67, 68]. As the time sensitive window of thalidomide
314 embryopathy is day 20-36 after fertilization (day 34-50 after the last menstrual cycle), when
315 vascular transition of the limbs is occurring and when proximal bony elements are condensing
316 and starting to differentiate (Figure 2A), inhibition of vascularization could well result in the
317 deficiency of or shortening of the forming long bones which could vary depending on the arterial
318 alterations occurring at that time [67, 68].

319
320 *-Misoprostol*

321 Misoprostol is a synthetic analog of Prostaglandin E1 and used to prevent gastric side effects
322 caused by nonsteroidal anti-inflammatory drugs. It also causes endometrial bleeding and uterine
323 contractions and so has been used as an abortifacient, particularly in Brazil [58, 72]. Sadly, it has
324 been shown to cause birth defects in children when the drug was used improperly [58]. The
325 injuries observed in such affected infants appears similar to the damage seen in thalidomide
326 damaged children [73] with limbs, facial and internal organs all affected. Moreover, the drug is
327 thought to cause vascular disruption in tissues likely due to increased uterine contractions that
328 Misoprostol induces (as part of the abortifacient process) resulting in hypoperfusion of the
329 embryo/fetus and blood entrapment/hemorrhaging [58, 74, 75].

330
331 Several other agents, including Valproic acid, can also cause vascular anomalies during
332 embryonic development. In chicken embryos valproate exposure produces a range of defects
333 similar to those in humans including neural and cardiac defects [76] and limb reduction defects
334 [77]. Furthermore, recent work demonstrated that popular anti-cancer antiangiogenic agents,
335 including Sunitinib, Sorafenib, Everolimus are also teratogenic and can cause a range of defects
336 including limb anomalies [78].

337
338 **Conclusion**

339 Blood vessels in the developing embryonic limbs change rapidly to accommodate the outgrowth
340 of the limbs and the differentiation processes needed to allow the complex combinations of
341 tissues to form. The morphology of the bony pattern of the limbs evolves as vascular pattern is
342 transforming to a mature, adult-like state. Noxious events which prevent the proper arterial
343 transitioning, can prevent vessels from correctly invading the forming precursors of the bones
344 resulting in a variety of defects. Similarly, injury resulting from hemorrhage, uterine constriction,
345 physical damage, drug exposure, molecular signalling failure or interference could also result in
346 such vascular changes. Such loss or inhibition of vessels or disruption of blood flow results in
347 poorly perfused tissues and bones leading to deficiency and/or malformation. As arterial
348 transition and bone formation are occurring at similar time points in embryonic development,
349 such vascular damage could explain a variety of limb anomalies.

350
351 Our understanding of the normal mechanisms underlying and controlling angiogenesis and how
352 the developing vasculature influences normal limb development, particularly the underlying
353 molecular signaling events, remains unclear. Indeed, recent models of pattern formation in limb
354 development have seemed solely focused on molecular mechanisms [8, 79, 80] yet largely ignore

355 the developing vasculature of the limbs which clearly fulfills an essential role in limb
356 development.

357

358 **Acknowledgements**

359 This article is dedicated to Dr David S. Packard Jr. With thanks to Dr John DeSesso, Dr Lewis B.
360 Holmes, Dr Mark Levinsohn, Dr David S. Packard Jr, Prof Lewis Wolpert for discussions on
361 vascular disruption, particularly arterial dysgenesis and limb defects.

362 This research did not receive any specific grant from funding agencies in the public, commercial,
363 or not-for-profit sectors.

364

365 **References**

366 1. N. Vargesson, Vascularisation of the developing chick limb bud: role of the TGFbeta
367 signaling pathway. *J Anat.* 202 (2003) 93-103.

368

369 2. A.I. Caplan, The vasculature and limb development. *Cell Differ.* 16 (1985) 1-11.

370

371 3. W. Risau, Mechanisms of angiogenesis. *Nature* 386 (1997) 671-674.

372

373 4. R. O’Rahilly, E. Gardner, The timing and sequence of events in the development of the limbs
374 in the human embryo. *Anat Embryol.* 148 (1975) 1-23.

375

376 5. C. Tickle, How the embryo makes a limb: determination, polarity and identity. *J Anat.* 227
377 (2015) 418-30.

378

379 6. R. Zeller, The temporal dynamics of vertebrate limb development, teratogenesis and
380 evolution. *Curr Opin Genet Dev.* 20 (2010) 384-390.

381

382 7. A.Zuniga, R. Zeller, S. Probst, The molecular basis of human congenital limb malformations.
383 *Wiley Interdiscip Rev Dev Biol.* 1 (2012) 803-822.

384 8. I. Delgado, M. Torres, Gradients, waves and timers, an overview of limb patterning models.
385 *Semin Cell Dev Biol.* 49 (2016) 109-115.

386 9. H.D. Senior, The development of the arteries of the human lower extremity. *Am J Anat.* 25
387 (1919) 55-95.

388

389 10. H.D. Senior, An interpretation of the recorded arterial anomalies of the human leg and foot. *J*
390 *Anat.* 53 (1919) 130-171.

391

392 11. R.F Drushel, D.G. Pechak, A.I. Caplan, The anatomy, ultrastructure and fluid dynamics of
393 the developing vasculature of the embryonic chick wing bud. *Cell Differ.* 16 (1985) 13-28.

394 12. E. M. Levinsohn, D. R. Hootnick, D. S. Packard Jr, Consistent arterial abnormalities
395 associated with a variety of congenital malformations of the human lower limb. *Invest Radiol.* 26
396 (1991) 364-373.

- 397 13. M. Rodriguez-Niedenfuhr, G. J. Burton, J. Deu, J. R. Sanudo, Development of the arterial
398 pattern in the upper limb of staged human embryos: normal development and anatomic
399 variations. *J. Anat.* 199 (2001) 407-417.
400
- 401 14. M. Rodriguez-Niedenfuhr, T. Vazquez, I. G. Parkin, J. R. Sanudo, Arterial patterns of the
402 human upper limb: update of anatomical variations and embryological development. *Eur J Anat.*
403 7 (2003) Suppl. 1:21-28.
404
- 405 15. E. Singer, Embryological pattern persisting in the arteries of the arm. *Anat Rec.* 55 (1933)
406 403-409.
407
- 408 16. H. D. Senior, A note on the development of the radial artery. *Anat Rec.* 32 (1926) 220-221.
- 409 17. D. S. Packard Jr, E. M. Levinsohn, D. R. Hootnick, Most human lower limb malformations
410 appear to result from postspecification insults. *Prog Clin Biol Res.* 383A (1993) 417-426.
- 411 18. H. D. Senior, Abnormal branching of the human popliteal artery. *Am J Anat.* 44 (1929) 111-
412 120.
413
- 414 19. E. M. Levinsohn, D. S. Packard, E. M. West, D. R. Hootnick, Arterial anatomy of chicken
415 embryo and hatchling. *Am J Anat.* 169 (1984) 377-405.
416
- 417 20. N. Vargesson, E. Laufer, Smad7 misexpression during embryonic angiogenesis causes
418 vascular dilation and malformations independently of vascular smooth muscle cell function. *Dev*
419 *Biol.* 240 (2001) 499-516.
- 420 21. C. Therapontos, L. Erskine, E. R. Gardner, W. D. Figg, N. Vargesson, Thalidomide induces
421 limb defects by preventing angiogenic outgrowth during early limb formation. *Proc Natl Acad*
422 *Sci U S A.* 106 (2009) 8573-8578.
- 423 22. C. Hamanishi, Congenital short femur. Clinical, genetic and epidemiological comparison of
424 the naturally occurring condition with that caused by thalidomide. *J Bone Joint Surg Br.* 62
425 (1980) 307-320.
- 426 23. D. R. Hootnick, E. M. Levinsohn, D. S. Packard Jr, Midline metatarsal dysplasia associated
427 with absent fibula. *Clin Orthop.* 150 (1980) 203-206.
- 428 24. D. R. Hootnick, D. S. Packard Jr, E. M. Levinsohn, A. Wladis, A vascular hypothesis for the
429 etiology of Clubfoot, in G. W. Simons (Eds), *The Clubfoot: The Present and a View of the*
430 *future.* Springer-Verlag, New York. 1994. pp. 48-58.
- 431 25. H. E. Hoyme, K. L. Jones, M. I. Van Allen, B. Saunders, K. Benirschke, Vascular
432 pathogenesis of transverse limb reduction defects. *J Pediatr* 101 (1982) 839-843.
- 433 26. D. S. Packard Jr, E. M. Levinsohn, D. R. Hootnick, Teratological implications of soft tissue
434 abnormalities found in human lower limbs with bony defect, in R. N. Feinberg, G. K. Sherer, R.

- 435 Auerbach (Eds), The Development of the Vascular System. Karger, Basel. Issues in Biomedicine
436 14 (1991) 157-169.
- 437 27. M. I. Van Allen, Fetal vascular disruptions: mechanisms and some resulting birth defects.
438 *Pediatr Ann.* 10 (1981) 219-233.
- 439 28. H. J. Bagg, Hereditary abnormalities of the limbs, their origin and transmission. II. A
440 morphological study with special reference to the etiology of clubfeet, syndactylism,
441 hypodactylism and congenital amputation in the descendants of x-rayed mice. *Am J Anat.* 43
442 (1929) 167.
- 443
444 29. H. S. N. Greene, J. A. Saxton, Hereditary brachydactylia and allied abnormalities in the rabbit.
445 *J Exp Med.* 69 (1939) 301-319.
- 446
447 30. L. A. Kennedy, T. V. Persaud, Pathogenesis of developmental defects induced in the rat by
448 amniotic sac puncture. *Acta Anat (Basel).* 97 (1977) 23-35.
- 449
450 31. C. Petter, J. Bourbon, J-P. Maltier, A. Jost, Simultaneous prevention of blood abnormalities
451 and hereditary congenital amputations in a Brachydactylous rabbit stock. *Teratology* 15 (1976)
452 149-158.
- 453 32. J. Chomiak, M. Horak, M. Masek, M. Frydrychova, P. Dungal P, Computed Tomographic
454 Angiography in Proximal Femoral Focal Deficiency. *J Bone Joint Surg Am.* 91 (2009) 1954-
455 1964.
- 456 33. D. R. Hootnick, E. M. Levinsohn, P. A. Randall, D. S. Packard, Vascular dysgenesis
457 associated with skeletal dysplasia of the lower limb. *J. Bone Joint Surg.* 62-A (1980) 1123-1129.
- 458 34. D. R. Hootnick, D. S. Packard Jr, E. M. Levinsohn, M. R. Lebowitz, J. P. Lubicky, The
459 anatomy of a congenitally short limb with clubfoot and ectrodactyly. *Teratology* 29 (1984) 155-
460 164.
- 461 35. L. Kruse, C. A. Gurnett, D. Hootnick, M. B. Dobbs, Magnetic resonance angiography in
462 clubfoot and vertical talus. *Clin Orthop Relat Res.* 467 (2009) 1250-1255.
- 463 36. M. I. Van Allen, H. E. Hoyme, K. L. Jones, Vascular pathogenesis of limb defects. I. Radial
464 artery anatomy in radial aplasia. *J Pediatr* 101 (1982) 832-838.
- 465 37. D. S. Packard Jr, E. M. Levinsohn, D. R. Hootnick, Extent of duplication in lower-limb
466 malformations suggests the time of the teratogenic insult. *Pediatrics* 91 (1993) 411-413.
- 467 38. H. Sodre, S. Bruschini, L. A. Mestriner, F. Miranda Jr, E. M. Levinsohn, D. S. Packard Jr, R.
468 J. Crider Jr, R. Schwartz, D. R. Hootnick, Arterial abnormalities in Talipes Equinovarus as
469 assessed by angiography and the Doppler technique. *J Pediatr Orthop.* 10 (1990) 101-104.

- 470 39. R. O’Rahilly, F Muller, Developmental stages in human embryos, in Developmental stages
471 in human embryos. Carnegie Institution of Washington. Publication 637. 1987. pp.1-263.
- 472 40. H. J. Merker, Considerations on the problem of critical period during the development of the
473 limb skeleton. *Birth Defects* 13 (1977) 179-202.
- 474 41. C. A. Goldfarb, L. B. Wall, Holt-Oram Syndrome. *J Hand Surg.* 39 (2014) 1646-1648.
- 475 42. C. T. DuPre, R. M. Fincher, Holt-Oram syndrome associated with hypoplastic peripheral
476 vasculature and midsystolic click. *South Med J.* 86 (1993) 453-456.
- 477 43. R. E. Tomlinson, Z. Li, Q. Zhang, B. C. Goh, Z. Li, D. L. J. Thorek, L. Rajbhandari, T. M.
478 Brushart, L. Minichiello, F. Zhou, A. Venkatesan, T. L. Clemens, NGF-TrkA signaling by
479 sensory nerves coordinates the vascularization and ossification of developing endochondral
480 bone. *Cell Rep.* 16 (2016) 2723-2735. Doi:10.1016/j.celrep.2016.08.002
- 481 44. S. K. Ramasamy, A. Kusumbe, T. Itkin, S. Gur-Cohen, T. Lapidot, R. H. Adams, Regulation
482 of hematopoiesis and osteogenesis by blood vessel-derived signals. *Ann Rev Cell and Dev Biol* 32
483 (2016) In Press. DOI: 10.1146/annurev-cellbio-111315-124936
- 484 45. T. Hashimoto, M. Tsuneki, T. R. Foster, J. M. Sanatan, H. Bai, M. Wang, H. Hu, J. J.
485 Hanisch, A. Dardik, Membrane-mediated regulation of vascular identity. *Birth Defects Res C*
486 *Embry Today* 108 (2016) 65-84.
- 487 46. A. H. James, Thrombosis in pregnancy and maternal outcomes. *Birth Defects Research (Part*
488 *C)* 105 (2015) 159-166.
- 489 47. C. F. Parsa, M. P. Robert, Thromboembolism and congenital malformations. *JAMA*
490 *Ophthalmol.* 131 (2013) 439-447.
- 491 48. M. I. Van Allen, J. C. Jackson, R. H. Knopp, R. Cone, In utero thrombosis and neonatal
492 gangrene in an infant of a diabetic mother. *Am J Med Genet.* 33 (1989) 323-327.
- 493 49. F. S. Vogel, J. L. McClenahan, Anomalies of major cerebral arteries associated with
494 congenital malformations of the brain. *Am J Pathol.* 28 (1952) 701-723.
- 495 50. D. Poswillo, The pathogenesis of the first and second branchial arch syndrome. *Oral Surg*
496 *Oral Med Oral Pathol.* 35 (1973) 302-328.
- 497 51. D. Poswillo, Hemorrhage in development of the face. *Birth Defects Orig Artic Ser.* 11 (1975)
498 61-81.
- 499 52. R. B. Stark, H. Washio, M. Deforest, S. Broque, The role of vascular deficiency in the
500 production of congenital malformation; preliminary report. *Plast Reconstr Surg.* 35 (1965) 478-
501 532.

- 502 53. C. T. Grabowski, Embryonic oxygen deficiency – a physiological approach to analysis of
503 teratological mechanisms. *Adv Teratol.* 4 (1970) 154.
- 504 54. W. Lenz, K. Knapp, Foetal malformations due to thalidomide. *German Med Monthly* 7
505 (1962) 253-258.
- 506 55. R. W. Smithells, C. G. Newman, Recognition of thalidomide defects. *J Med Genet.* 29 (1992)
507 716-723.
- 508 56. D. E. Poswillo, D. Sopher D, Malformation and deformation in the animal embryo.
509 *Teratology* 4 (1971) 498.
- 510 57. Y. Kino, Clinical and experimental studies of the congenital constriction band syndrome,
511 with an emphasis on it etiology. *J Bone Joint Surg Am.* 57 (1975) 636-643.
- 512 58. L. B. Holmes, Teratogen-induced limb defects. *Am J Med Genet.* 112 (2002) 297-303.
- 513 59. P. A. Dennery, Effects of oxidative stress on embryonic development. *Birth Defects Res C*
514 81 (2007) 155-162.
- 515 60. M. Cassina, G. A. Cagnoli, D. Zuccarello, E. Di Gianantonio, M. Clementi, Human
516 teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation.
517 *Eur J Med Genet* (2016) In Press. DOI: [10.1016/j.ejmg.2016.09.011](https://doi.org/10.1016/j.ejmg.2016.09.011)
- 518 61. R. J. D'Amato, M. S. Loughnan, E. Flynn, J. Folkman, Thalidomide is an inhibitor of
519 angiogenesis. *Proc Natl Acad Sci U S A.* 91 (1994) 4082-4085.
- 520 62. B. M. Kenyon, F. Browne, R. J. D'Amato. Effects of thalidomide and related metabolites in a
521 mouse corneal model of neovascularisation. *Exp Eye Res.* 64 (1997) 971-978.
- 522 63. A. Jurand, Early changes in limb buds of chick embryos after thalidomide treatment. *J*
523 *Embryol Exp Morphol.* 16 (1966) 289-300.
- 524 64. C. Mahony, L. Erskine, J. Niven, N. H. Greig, W. D. Figg, N. Vargesson, Pomalidomide is
525 nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. *Proc Natl Acad Sci*
526 *U S A.* 110 (2013) 12703-12708.
- 527 65. K. P. Tamilarasan, G. K. Kolluru, M. Rajaram, M. Indhumathy, R. Saranya, S. Chatterjee,
528 Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial
529 cells. *BMC Cell Biol.* 7 (2006) 17
- 530 66. T. Yabu, H. Tomimoto, Y. Taguchi, S. Yamaoka, Y. Igarashi, T. Okazaki, Thalidomide-
531 induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors,
532 and is antagonized by sphingosine-1-phosphate. *Blood* 106 (2005) 125-134.

- 533 67. N. Vargesson, Thalidomide-induced limb defects: resolving a 50-year old puzzle. *BioEssays*
534 31 (2009) 1327-1336.
- 535 68. N. Vargesson, Thalidomide-induced teratogenesis: history and mechanisms. *Birth Defects*
536 *Res C Embryo Today*. 105 (2015) 140-156.
- 537 69. N. Vargesson, Thalidomide embryopathy: an enigmatic challenge. *ISRN Developmental*
538 *Biology Vol 2013* (2013) Article ID 241016. <http://dx.doi.org/10.1155/2013/241016>
- 539 70. W. A. Maier, Thalidomide embryopathy and limb defects: experiences in habilitation of
540 children with ectromelias. *Arch. Dis. Childh.* 40 (1965) 154.
541
- 542 71. T. Tajima, T. Wada, A. Yoshizawa, T. Masuda, T. Okafuji, T. Nakayama, K. Hasuo, Internal
543 anomalies in thalidomide embryopathy: results of imaging screening by CT and MRI. *Clin*
544 *Radiol.* 71 (2016) 1199.e1-7 doi: 10.1016/j.crad.2016.07.015
- 545 72. C. H. Gonzalez, M. J. Marques-Dias, C. A. Kim, S. M. Sugayama, J. A. Da Paz, S. M.
546 Huson, L. B. Holmes, Congenital abnormalities in Brazilian children associated with misoprostol
547 misuse in first trimester pregnancy. *Lancet.* 351 (1998) 1624-1627.
- 548 73. M. T. Miller, L. Ventura, K. Stromland, Thalidomide and misoprostol: ophthalmologic
549 manifestations and associations both expected and unexpected. *Birth Defects Res A Clin Mol*
550 *Teratol.* 85 (2009) 667-676.
- 551 74. T. da Silva Dal Pizzol, F. P. Knop, S. S. Mengue, Prenatal exposure to misoprostol and
552 congenital anomalies: systematic review and meta-analysis. *Reprod Toxicol.* 22 (2006) 666-671.
- 553 75. F. R. Vargas, L. Schuler-Faccini, D. Brunoni, V. F. Meloni, S. M. Sugayama, L. Albano, J. C
554 Jr. Llerena, J. C. Almeida, A. Duarte, D. P. Cavalcanti, E. Goloni-Bertollo, A. Conte, G. Koren,
555 A. Addis, Prenatal exposure to misoprostol and vascular disruption defects: a case control study.
556 *Am J Med Genet.* 95 (2000) 302-306.
- 557 76. P. G. Kelly, C. M. Regan. Studies on valproate-induced perturbations of neurulation in the
558 explanted chick embryo. *Toxicology* 71 (1992) 137-144.
- 559 77. A. I. Whitsel, C. B. Johnson, C. J. Forehand. An in ovo chicken model to study the systemic
560 and localized teratogenic effects of valproic acid. *Teratology* 66 (2002) 153-163.
- 561 78. S. L. Beedie, C. Mahony, H. M. Walker, C. H. Chau, W. D. Figg, N. Vargesson, Shared
562 mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.
563 *Scientific Reports* 6:30038 (2016) DOI: 10.1038/srep30038.
- 564 79. C. Tabin, L. Wolpert L, Rethinking the proximodistal axis of the vertebrate limb in the
565 molecular era. *Genes Dev.* 21 (2007) 1433-1442.

- 566 80. A. Zuniga, Next generation limb development and evolution: old questions, new
567 perspectives. *Development* 142 (2015) 3810-3820.
- 568 81. D.R. Hootnick, D. S. Packard Jr. E. M. Levinsohn, R. Constantine, Postoperative necrosis in
569 Clubfoot: recent findings and review. *Orthopedics International Edition* 1 (1992) 48-68.
- 570
- 571

572

573 **Figure Legends**

574 **Figure 1**

575 **Vasculogenesis and Angiogenesis**

576 Endothelial cell precursors coalesce to form a clump of cells which then form a lumen to form
577 the primitive vessels in a process termed **vasculogenesis** – this is the de novo formation of the
578 first vessels. The vessels undergo **angiogenesis** following signal stimulation which result in
579 endothelial cell proliferation and migration. Once vessels have reached their target they can
580 recruit smooth muscle cells to become stable and to mature. In order to undergo further
581 angiogenesis the vascular smooth muscle coat needs to be shed. Some of the signalling
582 molecules involved in angiogenesis and vessel maintenance are detailed.

583 Figure reproduced with permission from N. Vargesson, Vascularisation of the developing chick
584 limb bud: role of the TGFbeta signalling pathway. *J. Anat.* 202 (2003) 93-103. [1]

585 **Figure 2**

586 **Limb development and limb vascularisation**

587 A.Generalised schematic of limb development. In the early limb bud Fgf8 is released from the
588 the apical ectodermal ridge (AER) and signals to the zone of polarising activity (ZPA) to
589 produce Shh which then establishes and maintains a feedback loop to allow mesenchymal cell
590 proliferation and limb bud outgrowth. As limb development proceeds differentiation of the bones
591 of the limb starts in a proximal to distal manner with the humerus forming first. The AER-ZPA
592 feedback loop is maintained and induces many other signals involved in limb formation and
593 patterning including Hox genes which also play a role in patterning the different bony elements.

594 B.Vascularisation of the developing chicken embryo forelimb. Upper panels are ink injected
595 limb buds at different stages of development to highlight the forming and rapidly changing
596 vasculature. The numbers refer to the stage of development of the embryo: 18 = day 2.5; 23 =
597 day 4; 26 = day 5; 30 = day 7. The limb bud grows out rapidly and the vasculature changes
598 rapidly to accommodate the outgrowth. Arrows demarcate the avascular zone between the
599 angiogenic vessels and the limb tip. Bottom panel are confocal microscope images of limbs at
600 the equivalent stages as the corresponding upper panel showing an antibody stain for vascular
601 smooth muscle actin. This highlights that the subclavian artery is the first and only artery to
602 recruit smooth muscle at around day 5 of development and by day 7 of development, the whole
603 of the subclavian artery and the proximal parts of the radial and ulnar arteries have smooth
604 muscle but very few other vessels are smooth muscle positive at this point. The recruitment of
605 smooth muscle to the subclavian artery coincides with the visualisation of the humerus
606 proximally. The recruitment of smooth muscle to the radial and ulnar arteries coincides with the
607 appearance of the radius and ulna condensations. Vascular smooth muscle negative vessels are
608 more angiogenic and permit rapid change to accommodate the outgrowing limb bud, however

609 they are also weaker and more susceptible to teratogenic insults. The black asterisk in the
610 handplate denotes vessel regression in the future areas where the digits will condense and form.

611 Figure A reproduced with modification from N. Vargesson, Thalidomide-induced teratogenesis:
612 history and mechanisms. Birth Defects Res C Embryo Today. 105 (2015) 140-156. [68]

613 Figure B reproduced with permission from N. Vargesson, Vascularisation of the developing
614 chick limb bud: role of the TGFbeta signalling pathway. J. Anat. 202 (2003) 93-103. [1]

615

616 **Figure 3**

617 **Embryo to adult arterial transition**

618 A Upper limb arterial transition. The vessel capillary plexus network seen in the very early limb
619 bud around Stage 12 (30 days) disappears and differentiates into the adult pattern following the
620 appearance of the skeletal elements.

621 Stage's refer to the Carnegie staging system of human embryo development (O'Rahilly and
622 Muller, 1987). Stage 12, 30 days (approx. 4.3 weeks); Stage 13, 32 days (approx. 4.6 weeks);
623 Stage 14, 33 days (approx. 4.7 weeks); Stage 15, 36 days (approx. 5.1 weeks); Stage 17, 41 days
624 (approx. 5.9 weeks); Stage 18, 44 days (approx. 6.3 weeks) and Stage 21, 51 days (approx. 7.3
625 weeks).

626 s, subclavian artery; a, axillary artery; b, brachial artery; r, radial artery; u, ulnar artery; ai,
627 anterior interosseous; H, humerus; U, ulna; R, radius.

628 B Lower limb arterial transition. 12mm stage (approx. 5.4 weeks), 14mm stage (approx 5.7
629 weeks), 18mm stage (approx. 6.3 days), 22mm stage (approx. 6.8 weeks), Adult stage (after 7th
630 week).

631 12mm stage of development a single-axis artery traverses the leg bud. By 14mm two arteries (TP
632 and PPS) originate posteriorly and the RPC branches anteriorly off the Interossea artery. By
633 18mm the anterior tibial artery develops as a continuation of the RPC. A branch (the RC)
634 develops off the PPS and anastomoses with the interossea artery. Five arteries now traverse the
635 forming leg. At 22mm stage of development there is regression of the distal part of the peronea
636 posterior superficialis and of the proximal part of the interossea artery. Note the presence of the
637 fibular (peroneal) artery (PE) which has formed from parts of the Axial, PPS, RC arteries. By the
638 7th week the adult pattern has emerged with the regression of the popliteal profunda.

639 Embryonic arteries: PP popliteal profunda; PS popliteal superficialis; PPS peronea posterior
640 superficialis; I interossea; RC ramus communicans inferior; RPC ramus perforans cruris; IS
641 ischiatic; TP tibialis posterior superficailis; P popliteal; PT posterior tibial; PE peroneal; AT
642 anterior tibial; RT recurrent tibial.

643 Muscles: MP popliteus; MTP tibialis posterior; MFH flexor hallucis.

644 Figure A reproduced with permission from M. Rodriguez-Niedenfuhr, G. J. Burton, J. Deu, J. R.
645 Sanudo, Development of the arterial pattern in the upper limb of staged human embryos: normal
646 development and anatomic variations. *J. Anat.* 199 (2001) 407-417. [13]

647 Figure B reproduced with permission from E. M. Levinsohn, D. R. Hootnick, D. S. Packard Jr.
648 Consistent arterial abnormalities associated with a variety of congenital malformations of the
649 human lower limb. *Invest Radiol.* 26 (1991) 364-373. [12]

650

651 **Figure 4**

652 **Altered/missing arterial patterns in legs with abnormalities**

653 Drawings of arterial patterns in A. Normal Limb; B. Limb with skeletal dysplasia with
654 abnormally short fibula – the anterior tibial and fibular (peroneal) arteries are absent and
655 functional embryonic arteries (I, PRS, RC) remain; C. Limb with skeletal dysplasia and absent
656 fibula with midline metatarsal dysplasia. Anterior tibial and fibular (peroneal) arteries are absent.
657 Functional embryonic arteries (I, RC) remain; D. Clubfoot, the anterior tibial artery is reduced. A
658 functional embryonic artery (PPS) is present.

659 These drawings are summary diagrams made following dissection of human tissues to analyse
660 the vessel pattern changes and the causation of the deformity [12, 17, 23, 33, 37].

661 Figure A-D from D. R. Hootnick, D. S. Packard Jr, E. M. Levinsohn, R. Constantine,
662 Postoperative necrosis in Clubfoot: recent findings and review. *Orthopedics International Edition*
663 1992; 1 (1): 48-68. Reprinted with permission from SLACK Incorporated [81]

664

665

666

667

668

669

670

671

672

673

674

675

676

Figure 1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)





Figure 4
[Click here to download high resolution image](#)



***Conflict of Interest Statement**

[Click here to download Conflict of Interest Statement: VARGESSON coi_disclosure.pdf](#)

***Conflict of Interest Statement**

[Click here to download Conflict of Interest Statement: HOOTNICK coi_disclosure.pdf](#)